Glucagon area under the curve (AUC) response to the hypoglycemic challenge, was significantly higher in the T2D-SSTR2 antagonist-treated group as compared to the T2D vehicle group (11336 ± 4524 vs. 3239 ± 2373, p < 0.05), with AUC values in the drug-treated group approaching those observed in the HFF controls (9704 ± 3579) (Figure 4D inset). Here, SSTR2 is linked to type 2 diabetes mellitus.